These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2374323)

  • 1. [Serum concentration of laminin in transitional cell carcinoma].
    Iwata S; Isobe H; Fujime M; Kitagawa R; Horikoshi S; Funabiki K; Koide H
    Nihon Hinyokika Gakkai Zasshi; 1990 Apr; 81(4):518-23. PubMed ID: 2374323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of serum laminin P1 in the diagnosis of transitional cell carcinoma of the bladder.
    Abou Farha KM; Menheere PP; Bruins JL; Kester AD; Janknegt R
    Eur Urol; 1992; 21(3):240-4. PubMed ID: 1499633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of serum laminin P1 values in patients with transitional cell carcinoma of the bladder.
    Mungan U; Kirkali G; Celebi I; Kirkali Z
    Urology; 1996 Sep; 48(3):496-500. PubMed ID: 8804512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation between basement membrane degradation and serum levels of laminin P1 in patients with transitional cell carcinoma of the bladder.
    Abou Farha KM; Menheere PP; Nieman FH; Janknegt RA; Arends JW
    Urol Int; 1993; 50(1):13-6. PubMed ID: 8434420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of serum laminin P1 as a diagnostic and monitoring parameter in transitional cell carcinoma of the bladder.
    AbouFarha KM; Menheere PP; Nieman FH; Arends JW; Janknegt RA
    Urol Int; 1992; 49(3):130-6. PubMed ID: 1466090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABO and rhesus blood groups as prognostic factors in transitional cell carcinomas of the upper urinary tract.
    Krogh J; Kvist E
    Urol Int; 1992; 48(1):9-13. PubMed ID: 1598741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Serum copper and zinc levels in patients with malignant neoplasm of the urogenital tract].
    Sanada S; Ogura K; Kiriyama T; Yoshida O
    Hinyokika Kiyo; 1985 Aug; 31(8):1299-316. PubMed ID: 4083194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma.
    Yaegashi H; Izumi K; Kadomoto S; Naito R; Makino T; Iwamoto H; Nohara T; Shigehara K; Kadono Y; Mizokami A
    Anticancer Res; 2019 Jan; 39(1):375-380. PubMed ID: 30591483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Level of CD4(+) CD25(high) CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its clinical significance].
    Zhu X; Hu XZ; Ma LL; Tian Y
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2269-72. PubMed ID: 20095340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of platelet-derived growth-factor B-chain mRNA and tumor angiogenesis in invasive transitional cell carcinoma of the upper urinary tract.
    Nakanishi K; Hiroi S; Kawai T; Torikata C
    Mod Pathol; 1997 Apr; 10(4):341-7. PubMed ID: 9110296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular metastases from transitional cell carcinoma of the urinary tract.
    Pe'er J; Zimmerman LE
    Graefes Arch Clin Exp Ophthalmol; 1984; 221(4):137-41. PubMed ID: 6323274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA19-9 as a serum marker for poor prognosis in urothelial carcinoma.
    Sashide K; Isobe H; Wakumoto Y; Hanazawa K; Fujita K; Fujime M
    Urol Int; 2004; 72(2):112-7. PubMed ID: 14963350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.
    Harker WG; Meyers FJ; Freiha FS; Palmer JM; Shortliffe LD; Hannigan JF; McWhirter KM; Torti FM
    J Clin Oncol; 1985 Nov; 3(11):1463-70. PubMed ID: 4056840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of preoperative renal function and gross hematuria for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma.
    Hashimoto T; Nakashima J; Kashima T; Hirasawa Y; Shimodaira K; Gondo T; Nakagami Y; Namiki K; Horiguchi Y; Ohno Y; Ohori M; Tachibana M
    Int J Urol; 2017 Feb; 24(2):111-116. PubMed ID: 27875859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum concentration of laminin in renal cell carcinoma].
    Iwata S; Isobe H; Fujime M; Kitagawa R; Horikoshi S; Funabiki K; Koide H
    Nihon Hinyokika Gakkai Zasshi; 1989 Jun; 80(6):870-4. PubMed ID: 2796105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA19-9 as a serum marker for poor prognosis in urothelial carcinoma.
    Suzuki K
    Urol Int; 2004; 73(4):357. PubMed ID: 15604583
    [No Abstract]   [Full Text] [Related]  

  • 17. Circulating biomarkers to guide systemic therapy for urothelial carcinoma.
    Abbosh PH; Rosenberg JE; Plimack ER
    Urol Oncol; 2016 Nov; 34(11):502-509. PubMed ID: 27751785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ca 125 as a marker of tumor activity in advanced urothelial malignancy.
    Izes JK; Dyer MW; Callum MG; Bankes P; Libertino JA; Caffrey JA
    J Urol; 2001 Jun; 165(6 Pt 1):1908-13. PubMed ID: 11371879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors.
    Langner C; Ratschek M; Tsybrovskyy O; Schips L; Zigeuner R
    J Histochem Cytochem; 2003 Aug; 51(8):1097-9. PubMed ID: 12871991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.